10-Q: Scientific Industries Q1 2026 Financial Results

Scientific Industries reports a reduced net loss of $1.59 million for Q1 2026, driven by revenue growth and cost-cutting initiatives.

Summary

• Net loss for the three months ended March 31, 2026, was $1.59 million, compared to $1.78 million in the same period of 2025.
• Net revenues increased 30.2% to $1.23 million, up from $0.94 million in Q1 2025.
• Gross profit margin improved to 38.3% from 36.5% in the prior year period.
• Operating expenses decreased to $2.14 million from $2.43 million, reflecting successful cost-reduction efforts.
• Cash and cash equivalents stood at $0.80 million as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report; while the company successfully reduced losses and improved margins, the ongoing going concern risk and reliance on cash reserves from a past divestiture remain significant headwinds.

Positives

• Revenue growth of 30.2% year-over-year.
• Gross profit margin expansion to 38.3%.
• Significant reduction in operating expenses, particularly in general and administrative costs.
• Successful implementation of cost-cutting initiatives in the Bioprocessing Systems segment.

Negatives

• Continued net losses from operations.
• Negative cash flow from operations of $0.99 million for the quarter.
• Accumulated deficit of $36.74 million.
• Reliance on historical equity financings to support operations.

Risks

• Substantial doubt regarding the ability to continue as a going concern without successful execution of the current operating plan.
• Expectation of continued negative cash flows from operations in the foreseeable future.
• Dependence on the success of the Bioprocessing Systems segment, which remains in a start-up stage.
• Market competition and potential failure to achieve projected revenue growth.

Future Outlook

Management expects that cash generated from the Genie Division sale and related agreements will be sufficient to support business operations for at least one year from the date of the filing, though there is no assurance that the operating plan will be successful.

Management Comments

• Management believes cash on hand is sufficient to fund operations for at least one year.
• The company continues to focus on reducing operating costs and conserving cash.

Industry Context

StockSavvy.ai notes that the company is transitioning from a legacy laboratory equipment business to a specialized bioprocessing systems provider, a sector currently experiencing high R&D intensity and consolidation pressure.

Comparison to Industry Standards

• The company's gross margin of 38.3% is generally consistent with mid-tier laboratory equipment manufacturers.
• The high R&D spend relative to revenue is typical for companies in the early-stage bioprocessing technology space.

Legal Proceedings

• None disclosed.

Related Party Transactions

• Consulting agreement with Director John Nicols, who agreed to a 50% reduction in fees effective February 1, 2026.

Stakeholder Impact

• Shareholders face continued dilution risk if the company fails to reach profitability and requires further equity financing.
• Employees in the Bioprocessing segment have been impacted by recent reductions in force.

Next Steps

• Continue execution of the Bioprocessing Systems growth strategy.
• Monitor cash burn and adherence to the current operating plan.
• Evaluate impact of upcoming accounting standards (ASU 2025-11).

Key Dates

Recommendation

The company is in a precarious financial position with recurring losses and a going concern warning, making it a high-risk hold until the Bioprocessing segment demonstrates sustainable revenue growth.

Keywords

Bioprocessing, Laboratory Equipment, Scientific Industries, SCND, Financial Results, 10-Q